|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000029907 |
|
最近更新日期: Date of Last Refreshed on: |
2020-02-16 19:40:37 |
|
注册时间: Date of Registration: |
2020-02-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
新型冠状病毒(COVID-19)感染临床风险预警模型的构建与评价 |
|
Public title: |
Study for construction and assessment of early warning score of the clinical risk of novel coronavirus infected patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新型冠状病毒感染临床风险预警模型的构建与评价 |
|
Scientific title: |
Study for construction and assessment of early warning score of the clinical risk of novel coronavirus infected patients (COVID-19) |
|
研究课题代号(代码): Study subject ID: |
2020YFS0009 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
姚蓉 |
研究负责人: |
姚蓉 |
|
Applicant: |
Yao, Rong |
Study leader: |
Yao, Rong |
|
申请注册联系人电话: Applicant telephone: |
+86 18980601415 |
研究负责人电话: Study leader's telephone: |
+86 18980601415 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1037070596@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1037070596@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市国学巷37号四川大学华西医院 |
研究负责人通讯地址: |
四川省成都市国学巷37号四川大学华西医院 |
|
Applicant address: |
37 Guoxue Lane, Chengdu, Sichuan, China |
Study leader's address: |
37 Guoxue Lane, Chengdu, Sichuan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院急诊科 |
||
|
Applicant's institution: |
Emergency department of West China Hospital, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
否/No |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 |
||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Lane, Chengdu, Sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川省科技厅应对新型冠状病毒科技攻关应急项目(2020YFS0009) |
||||||||||||||||||||||
|
Source(s) of funding: |
Science and Technology Department of Sichuan Province (2020YFS0009) |
||||||||||||||||||||||
|
Target disease: |
COVID-19 |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1.分析新型冠状病毒感染病例的临床特征及危险因素。 2.与本团队前期建立的流感病毒感染病例数据库进行对比,探索早期鉴别的临床要点。 3.通过已知病例分析及参考现有循证证据,构建基于临床指标的新型冠状病毒感染病例临床风险预警模型(或评分)。 4.对模型的效度及信度进行验证。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To analyze the clinical features and risk factors of COVID-19 infected cases. 2. To explore the clinical key points of early differentiation between COVID-19 and influenza virus infection. 3. To establish a early warning score warning model based on clinical index. 4. Verify the validity and reliability of the model. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
无 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
N/A |
||||||||||||||||||||||
|
纳入标准: |
符合COVID-19疑似和确诊标准的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients who meet the suspected or confirmed diagnostic criteria of COVID-19. |
||||||||||||||||||||||
|
排除标准: |
无 |
||||||||||||||||||||||
|
Exclusion criteria: |
N/A |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-01-01 00:00:00至 To 2020-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-01-01 00:00:00 至 To 2020-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不涉及 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2021年1月31日 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Jan 31,2021 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |